July 29，Fosun Pharmaceutical release announcement，It is intended to acquire Gland Pharma Limited of about 86.08%of the equity of Gland Pharma Limited through the holding subsidiary of the holding subsidiary，Among them, the acquirer will be paid by ENOXAPARIN (& ldquo; Yinuo heparin & rdquo;) on sale in the United States.。

 

  It is understood，Gland is the first injection pharmaceutical manufacturing enterprise approved by the United States FDA in India，GMP authentication of the global regulations stake sports betting appmarkets，My stake betting appIts business income mainly comes from the United States and Europe。Products include heparin sodium、Yingo Hepatin sodium injection、Rockelobine injection、Reorganized human insulin, etc.。

 

  Fosun Pharmaceutical said in the announcement，After the transaction is completed，GLAND will become an important international drug manufacturing and registration platform for the group，At the same time，Through the management of GLAND，It will help the Group to promote the industrial upgrade of the drug manufacturing business、Improve the Group's share in the injection market。

 

  It is worth mentioning that it is，Make a big merger for overseas mergers and acquisitions，Fosun Pharmaceutical is not the only one。According to media reports，​​China Resources Group is about to hold hands with Australian cancer therapy provider Genesis Car，Forecast mergers and acquisitions reached 1.7 billion A $ A $。

 

  Since July，Including Shutai God、Zixin Pharmaceutical、Jiu'an Medical and many other A -share listed companies have issued an announcement for overseas acquisitions。

 

  Shu Tai Shen released an announcement on July 18，All -funded subsidiaries Shu Tai Shen Hong Kong Investment Co., Ltd. uses its own funds 18.1 million euros to subscribe to the newly issued Class C preferred shares issued by INFLARX GMBH in Germany; Zixin Pharmaceutical announced on July 22，Company intends to sign the "Investment Stake Sports Bettingstake online sports bettingFramework Agreement" with NABSYS 2.0，By the first increase of 6 million US dollars or equivalent of RMB，Subsequent investment at most 36 million US dollars or equivalent of RMB，Total 42 million US dollars or equivalent worth RMB，Eventually 67%equity of Nabsys 2.0。

 

   & ldquo; The speed of overseas mergers and acquisitions of Chinese companies is getting faster and faster、The scale is also getting larger and larger。& rdquo;。

 

  Domestic high -quality target scarcity

 

  In recent years，With the improvement of the country's importance to the great health industry of medicine，Domestic multi -way capital has integrated and acquired industry in the industry，And there is a strongest trend，This also makes the price of the acquisition of the target rising.。

 

  Qu Yan introduced to reporters，At present, there are a lot of companies in the pharmaceutical and biological industry，But the high -quality target is getting less and less，and most of them are controlled by foreign companies。Domestic pharmaceutical companies to conduct overseas mergers and acquisitions are the general trend。

 

  It is worth mentioning that it is，The major changes in the domestic pharmaceutical industry are also one of the booster factors that companies turn to overseas medical treatment。Current，In order to solve the 痼 disease in the pharmaceutical industry itself，The national regulatory authorities have successively launched My stake betting appthe consistency evaluation stake betting appof generic drugs、Control hospital medication ratio、GMP certification, etc.，This has led to the challenge of the profit margin of pharmaceutical companies。

 

  & ldquo; Pay attention to the development of new drugs、Improve the quality of the medicine、Obtaining heavy varieties becomes an inevitable road for enterprise transformation。& rdquo; People who are engaged in the pharmaceutical industry are explained to reporters，Most domestic companies are generic drug production enterprises，Product research and development capabilities are relatively weak，Overseas mergers and acquisitions is a way for enterprises to quickly improve their strength。

 

  but，Chinese pharmaceutical companies also have certain risks for overseas mergers and acquisitions。

 

   & ldquo; Overseas M & A competition is also very intense。& rdquo; Investors in the pharmaceutical industry mentioned above told reporters，Some multinational foreign pharmaceutical companies have a high ability to acquire，They have more mature and rich acquisition experience。Compared to these companies，Chinese companies are choosing the target、There is still a gap in risk assessment。& ldquo; The cycle of the new drug research and development is very long，You need long -term capital investment，The risk of the successful realization of the new medicine is very risky，Stake Sports BettingThis challenge for companies My stake betting appthat are new to overseas investment markets & rdquo;。